Oral semaglutide 25 mg in adults with overweight or obesity

Oral semaglutide 25 mg in adults with overweight or obesity

New England Journal of Medicine

2025

Study summary

Oral semaglutide 25 mg was studied for weight management in adults with overweight or obesity.

Peptides studied

Stack studied

Metabolic Stack

Key findings

Oral semaglutide 25 mg led to greater mean weight reduction than placebo.

Study details

Study type

randomized clinical trial

Journal

New England Journal of Medicine

DOI / PubMed

10.1056/NEJMoa2403347

Year

2025

Explore peptide profiles

Discover compounds, understand their mechanisms, and explore the research behind each peptide.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.